FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159530258> ?p ?o ?g. }

• W3159530258 endingPage "496" @default.
• W3159530258 startingPage "484" @default.
• W3159530258 abstract "In 2018, the US National Institute on Aging and the Alzheimer's Association proposed a purely biological definition of Alzheimer's disease that relies on biomarkers. Although the intended use of this framework was for research purposes, it has engendered debate and challenges regarding its use in everyday clinical practice. For instance, cognitively unimpaired individuals can have biomarker evidence of both amyloid β and tau pathology but will often not develop clinical manifestations in their lifetime. Furthermore, a positive Alzheimer's disease pattern of biomarkers can be observed in other brain diseases in which Alzheimer's disease pathology is present as a comorbidity. In this Personal View, the International Working Group presents what we consider to be the current limitations of biomarkers in the diagnosis of Alzheimer's disease and, on the basis of this evidence, we propose recommendations for how biomarkers should and should not be used for diagnosing Alzheimer's disease in a clinical setting. We recommend that Alzheimer's disease diagnosis be restricted to people who have positive biomarkers together with specific Alzheimer's disease phenotypes, whereas biomarker-positive cognitively unimpaired individuals should be considered only at-risk for progression to Alzheimer's disease. In 2018, the US National Institute on Aging and the Alzheimer's Association proposed a purely biological definition of Alzheimer's disease that relies on biomarkers. Although the intended use of this framework was for research purposes, it has engendered debate and challenges regarding its use in everyday clinical practice. For instance, cognitively unimpaired individuals can have biomarker evidence of both amyloid β and tau pathology but will often not develop clinical manifestations in their lifetime. Furthermore, a positive Alzheimer's disease pattern of biomarkers can be observed in other brain diseases in which Alzheimer's disease pathology is present as a comorbidity. In this Personal View, the International Working Group presents what we consider to be the current limitations of biomarkers in the diagnosis of Alzheimer's disease and, on the basis of this evidence, we propose recommendations for how biomarkers should and should not be used for diagnosing Alzheimer's disease in a clinical setting. We recommend that Alzheimer's disease diagnosis be restricted to people who have positive biomarkers together with specific Alzheimer's disease phenotypes, whereas biomarker-positive cognitively unimpaired individuals should be considered only at-risk for progression to Alzheimer's disease. The changing definition of Alzheimer's diseaseWidely used criteria for the diagnosis of Alzheimer's disease were established in 1984. These criteria outlined a typical clinical picture, recommended laboratory testing to exclude other causes of dementia, required neuropathological examination for a definitive diagnosis, and categorised individuals without pathological verification as having probable or possible Alzheimer's disease.1 For more than 20 years, Alzheimer's disease remained a probabilistic clinical-pathological syndrome; syndromes are notoriously non-specific and the Alzheimer's disease syndrome was no exception. Full-Text PDF" @default.
• W3159530258 created "2021-05-10" @default.
• W3159530258 creator A5002183686 @default.
• W3159530258 creator A5016975630 @default.
• W3159530258 creator A5020179909 @default.
• W3159530258 creator A5022818431 @default.
• W3159530258 creator A5032025339 @default.
• W3159530258 creator A5034401588 @default.
• W3159530258 creator A5040711752 @default.
• W3159530258 creator A5051868596 @default.
• W3159530258 creator A5052536571 @default.
• W3159530258 creator A5059020389 @default.
• W3159530258 creator A5060487287 @default.
• W3159530258 creator A5062628381 @default.
• W3159530258 creator A5062695564 @default.
• W3159530258 creator A5068394264 @default.
• W3159530258 creator A5072592799 @default.
• W3159530258 creator A5075804608 @default.
• W3159530258 creator A5076349608 @default.
• W3159530258 creator A5087220534 @default.
• W3159530258 creator A5089411086 @default.
• W3159530258 creator A5091618250 @default.
• W3159530258 date "2021-06-01" @default.
• W3159530258 modified "2023-10-16" @default.
• W3159530258 title "Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group" @default.
• W3159530258 cites W1507743940 @default.
• W3159530258 cites W1543528560 @default.
• W3159530258 cites W1577433680 @default.
• W3159530258 cites W1825683130 @default.
• W3159530258 cites W1892456310 @default.
• W3159530258 cites W1936322111 @default.
• W3159530258 cites W1966645427 @default.
• W3159530258 cites W1971032265 @default.
• W3159530258 cites W1975005502 @default.
• W3159530258 cites W1978991736 @default.
• W3159530258 cites W1993023011 @default.
• W3159530258 cites W1996314668 @default.
• W3159530258 cites W2026970282 @default.
• W3159530258 cites W2064955232 @default.
• W3159530258 cites W2071134735 @default.
• W3159530258 cites W2082429191 @default.
• W3159530258 cites W2084121214 @default.
• W3159530258 cites W2103440561 @default.
• W3159530258 cites W2106931873 @default.
• W3159530258 cites W2115017507 @default.
• W3159530258 cites W2115790527 @default.
• W3159530258 cites W2116709840 @default.
• W3159530258 cites W2116886795 @default.
• W3159530258 cites W2122522567 @default.
• W3159530258 cites W2124030567 @default.
• W3159530258 cites W2129497119 @default.
• W3159530258 cites W2129823286 @default.
• W3159530258 cites W2138190873 @default.
• W3159530258 cites W2143461767 @default.
• W3159530258 cites W2144707045 @default.
• W3159530258 cites W2150070900 @default.
• W3159530258 cites W2156220037 @default.
• W3159530258 cites W2157110881 @default.
• W3159530258 cites W2168335347 @default.
• W3159530258 cites W2168357345 @default.
• W3159530258 cites W2174753847 @default.
• W3159530258 cites W2239344903 @default.
• W3159530258 cites W2302528231 @default.
• W3159530258 cites W2309442902 @default.
• W3159530258 cites W2473313434 @default.
• W3159530258 cites W2494586080 @default.
• W3159530258 cites W2555821841 @default.
• W3159530258 cites W2582524520 @default.
• W3159530258 cites W2592378632 @default.
• W3159530258 cites W2600084629 @default.
• W3159530258 cites W2603308917 @default.
• W3159530258 cites W2620810124 @default.
• W3159530258 cites W2621105275 @default.
• W3159530258 cites W2623521763 @default.
• W3159530258 cites W2625796101 @default.
• W3159530258 cites W2753970170 @default.
• W3159530258 cites W2756224036 @default.
• W3159530258 cites W2760832975 @default.
• W3159530258 cites W2763258862 @default.
• W3159530258 cites W2766763626 @default.
• W3159530258 cites W2768782243 @default.
• W3159530258 cites W2769512083 @default.
• W3159530258 cites W2769602825 @default.
• W3159530258 cites W2778838015 @default.
• W3159530258 cites W2785757836 @default.
• W3159530258 cites W2786030143 @default.
• W3159530258 cites W2788507110 @default.
• W3159530258 cites W2790793038 @default.
• W3159530258 cites W2791135917 @default.
• W3159530258 cites W2794454775 @default.
• W3159530258 cites W2794653302 @default.
• W3159530258 cites W2794659745 @default.
• W3159530258 cites W2798054687 @default.
• W3159530258 cites W2804922289 @default.
• W3159530258 cites W2806938337 @default.
• W3159530258 cites W2894273961 @default.
• W3159530258 cites W2897964327 @default.
• W3159530258 cites W2898037283 @default.

• next